The United Nations Office at Geneva
Multimedia Newsroom
COVID-19: UN health agency issues conditional advice against using remdesivir
Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.
Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.
“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.
According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”
But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.
Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.
While a minority of people will still choose to use it, the majority would not, based on the available data, he said.
“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”
Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.
“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.
“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
- SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
Similar Stories
1
1
1
Edited News | ICRC , OHCHR , UNHCR
Myanmar’s military has continued to launch airstrikes and other attacks against opposition forces in the devastated country, one week since a 7.7 magnitude earthquake struck and despite announcing a ceasefire, UN human rights chief Volker Türk said on Friday.
1
1
1
Edited News | OHCHR
UN Deputy High Commissioner for Human Rights Nada Al-Nashif on Tuesday presented a report on the human rights situation in the Democratic Republic of Congo, detailing the continued violations of human rights as a result of the offensive launched by the Rwandan-backed M23 in eastern DRC.
1
1
1
Edited News | OCHA , UNICEF , IFRC
UN humanitarians and partners on Tuesday expressed deep shock at the killing of 15 colleagues on duty in southern Gaza whose remains were recovered from a shallow grave after a week-long rescue operation, noting that one worker is still missing.
1
1
1
Edited News | UNICEF , OCHA , WHO , UNHCR
Myanmar earthquake latest: window for lifesaving support is closing, say UN humanitarians
As the death toll continues to rise in earthquake-struck Myanmar, UN humanitarians have been rushing to support severely deprived and traumatized victims, warning that the window for lifesaving response is closing.
1
1
1
Edited News | OCHA , UNWOMEN , WHO
Lifesaving supplies in Gaza continue to run dangerously low, nearly four weeks into the total aid blockade and deadly bombardment of the enclave by Israel, UN humanitarians said on Friday.
1
1
1
Edited News | UNICEF
As Yemen’s conflict reaches 10-year mark, over half a million children severely malnourished
In Yemen, a decade of conflict has been catastrophic for the country’s children living under the threat of airstrikes and staggeringly high malnutrition rates, the UN Children’s Fund (UNICEF) said on Tuesday.
2
1
2
Press Conferences , Edited News | UNAIDS
Amid continuing uncertainty about the impact of deep US funding cuts to humanitarian work worldwide, the head of the UN agency coordinating the fight against HIV-AIDS warned that an addition 6.3 million people will die in the next four years, unless the support is reinstated.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office today published a report detailing how death, injury and lasting family separation are among the traumatic events that have upended the lives of Ukraine’s children in the three years since the Russian Federation launched its full-scale invasion.
1
1
1
Edited News | UNRWA , UNICEF , IFRC
Israel’s renewed bombing campaign and intensifying ground operation in Gaza are reversing gains achieved during the brief ceasefire, UN humanitarians said on Friday from inside the devastated enclave.
2
1
2
Press Conferences , Edited News | HRC
The Human Rights Council on Wednesday heard gruesome testimony of torture, rape and execution of Ukrainian detainees and soldiers by Russian forces, as a high-level independent probe delivered its latest mandated report in Geneva.
2
23
1
1
Edited News , Press Conferences | UNITED NATIONS
Cyprus talks result in trust-building measures, show ‘new atmosphere’ among divided island’s leaders, says UN’s Guterres
UN-led efforts to kick-start talks on the divided Mediterranean island of Cyprus have resulted in agreements on new trust-building measures and also underscored the positive “new atmosphere” surrounding the discussions, Secretary-General António Guterres said on Tuesday.
1
62
1
2
Edited News , Images | UNITED NATIONS , UNOG
Fresh talks over the future of Cyprus continued on Tuesday as representatives of the divided Mediterranean island gathered at the UN in Geneva along with guarantors Greece, Türkiye and the United Kingdom at the request of UN chief António Guterres.